In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Authors:
Open Access
- 7 January 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Abstract
Targeting the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis with monoclonal antibodies (mAbs) represents a crucial breakthrough in anticancer therapy, but mAbs are limited by their poor oral bioavailability, adverse events in multiple organ systems, and primary, adaptive, and acquired resistance, amongst other issues. More recently, the advent of small molecule inhibitors that target the PD-1/PD-L1 axis have shown promising cellular inhibitory activity and the potential to counteract the disadvantages of mAbs. In this study, structure-based virtual screening identified small molecule inhibitors that effectively inhibited the PD-1/PD-L1 interaction. Six of those small molecule inhibitors were applied to cell-based experiments targeting PD-1: CH-1, CH-2, CH-3, CH-4, CH-5, and CH-6. Of all 6, CH-4 displayed the lowest cytotoxicity and strongest inhibitory activity towards the PD-1/PD-L1 interaction. The experiments revealed that CH-4 inhibited the interaction of soluble form PD-L1 (sPD-L1) with PD-1 surface protein expressed by KG-1 cells. Investigations into CH-4 analogs revealed that CH-4.7 effectively blocked the PD-1/sPD-L1 interaction, but sustained the secretion of interleukin-2 and interferon-γ by Jurkat cells. Our experiments revealed a novel small molecule inhibitor that blocks the interaction of PD-1/sPD-L1 and potentially offers an alternative PD-1 target for immune checkpoint therapy.Keywords
Funding Information
- China Medical University, Taiwan (CMU108-S-34)
- Taipei Medical University, Taiwan (TMU106-AE1-B04)
This publication has 53 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The Protein Data Bank at 40: Reflecting on the Past to Prepare for the FutureStructure, 2012
- The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune PathologyPLOS Pathogens, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moietiesNucleic Acids Research, 2010
- PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In VitroInvestigative Ophthalmology & Visual Science, 2008
- PD‐L2:PD‐1 involvement in T cell proliferation, cytokine production, and integrin‐mediated adhesionEuropean Journal of Immunology, 2005
- GEMDOCK: A generic evolutionary method for molecular dockingProteins: Structure, Function, and Bioinformatics, 2004
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- The NCI Drug Information System. 3. The DIS chemistry moduleJournal of Chemical Information and Computer Sciences, 1986